These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 29921891)

  • 1. Management of Low and Intermediate Risk Adult Rhabdomyosarcoma: A Pooled Survival Analysis of 553 Patients.
    Elsebaie MAT; Amgad M; Elkashash A; Elgebaly AS; Ashal GGEL; Shash E; Elsayed Z
    Sci Rep; 2018 Jun; 8(1):9337. PubMed ID: 29921891
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of intermediate risk rhabdomyosarcoma and undifferentiated sarcoma with alternating cycles of vincristine/doxorubicin/cyclophosphamide and etoposide/ifosfamide.
    Arndt CA; Nascimento AG; Schroeder G; Schomberg PJ; Neglia JP; Sencer SF; Silberman TL; Moertel CL; Tillisch JK; Miser JS
    Eur J Cancer; 1998 Jul; 34(8):1224-9. PubMed ID: 9849484
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intensive induction chemotherapy and delayed irradiation in the management of parameningeal rhabdomyosarcoma.
    Smith SC; Lindsley SK; Felgenhauer J; Hawkins DS; Douglas JG
    J Pediatr Hematol Oncol; 2003 Oct; 25(10):774-9. PubMed ID: 14528099
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reduction of cyclophosphamide dose for patients with subset 2 low-risk rhabdomyosarcoma is associated with an increased risk of recurrence: A report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group.
    Walterhouse DO; Pappo AS; Meza JL; Breneman JC; Hayes-Jordan A; Parham DM; Cripe TP; Anderson JR; Meyer WH; Hawkins DS
    Cancer; 2017 Jun; 123(12):2368-2375. PubMed ID: 28211936
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intensive Multiagent Therapy, Including Dose-Compressed Cycles of Ifosfamide/Etoposide and Vincristine/Doxorubicin/Cyclophosphamide, Irinotecan, and Radiation, in Patients With High-Risk Rhabdomyosarcoma: A Report From the Children's Oncology Group.
    Weigel BJ; Lyden E; Anderson JR; Meyer WH; Parham DM; Rodeberg DA; Michalski JM; Hawkins DS; Arndt CA
    J Clin Oncol; 2016 Jan; 34(2):117-22. PubMed ID: 26503200
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of results of a pilot study of alternating vincristine/doxorubicin/cyclophosphamide and etoposide/ifosfamide with IRS-IV in intermediate risk rhabdomyosarcoma: a report from the Children's Oncology Group.
    Arndt CA; Hawkins DS; Meyer WH; Sencer SF; Neglia JP; Anderson JR
    Pediatr Blood Cancer; 2008 Jan; 50(1):33-6. PubMed ID: 17091486
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rhabdomyosarcoma and undifferentiated sarcoma in the first two decades of life: a selective review of intergroup rhabdomyosarcoma study group experience and rationale for Intergroup Rhabdomyosarcoma Study V.
    Raney RB; Anderson JR; Barr FG; Donaldson SS; Pappo AS; Qualman SJ; Wiener ES; Maurer HM; Crist WM
    J Pediatr Hematol Oncol; 2001 May; 23(4):215-20. PubMed ID: 11846299
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of prognostic factors in patients with nonmetastatic rhabdomyosarcoma treated on intergroup rhabdomyosarcoma studies III and IV: the Children's Oncology Group.
    Meza JL; Anderson J; Pappo AS; Meyer WH;
    J Clin Oncol; 2006 Aug; 24(24):3844-51. PubMed ID: 16921036
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Indications for radiotherapy and chemotherapy after complete resection in rhabdomyosarcoma: A report from the Intergroup Rhabdomyosarcoma Studies I to III.
    Wolden SL; Anderson JR; Crist WM; Breneman JC; Wharam MD; Wiener ES; Qualman SJ; Donaldson SS
    J Clin Oncol; 1999 Nov; 17(11):3468-75. PubMed ID: 10550144
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rhabdomyosarcoma of the parotid region occurring in childhood and adolescence. A report from the Intergroup Rhabdomyosarcoma Study Group.
    Walterhouse DO; Pappo AS; Baker KS; Parham DM; Anderson JR; Donaldson SS; Paidas CN; Womer RB; Crist WM
    Cancer; 2001 Dec; 92(12):3135-46. PubMed ID: 11753993
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
    Hagemeister FB
    Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Complete second look operation and radiotherapy in locally advanced non-alveolar rhabdomyosarcoma in children: A report from the AIEOP soft tissue sarcoma committee.
    Cecchetto G; Carretto E; Bisogno G; Dall'Igna P; Ferrari A; Scarzello G; Donfrancesco A; Alaggio R; Indolfi P; Carli M
    Pediatr Blood Cancer; 2008 Nov; 51(5):593-7. PubMed ID: 18668515
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Benefit of intensified therapy for patients with local or regional embryonal rhabdomyosarcoma: results from the Intergroup Rhabdomyosarcoma Study IV.
    Baker KS; Anderson JR; Link MP; Grier HE; Qualman SJ; Maurer HM; Breneman JC; Wiener ES; Crist WM
    J Clin Oncol; 2000 Jun; 18(12):2427-34. PubMed ID: 10856103
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ifosfamide and etoposide are superior to vincristine and melphalan for pediatric metastatic rhabdomyosarcoma when administered with irradiation and combination chemotherapy: a report from the Intergroup Rhabdomyosarcoma Study Group.
    Breitfeld PP; Lyden E; Raney RB; Teot LA; Wharam M; Lobe T; Crist WM; Maurer HM; Donaldson SS; Ruymann FB
    J Pediatr Hematol Oncol; 2001 May; 23(4):225-33. PubMed ID: 11846301
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of non-metastatic rhabdomyosarcomas in childhood and adolescence. Results of the second study of the International Society of Paediatric Oncology: MMT84.
    Flamant F; Rodary C; Rey A; Praquin MT; Sommelet D; Quintana E; Theobald S; Brunat-Mentigny M; Otten J; Voûte PA; Habrand JL; Martelli H; Barrett A; Terrier-Lacombe MJ; Oberlin O
    Eur J Cancer; 1998 Jun; 34(7):1050-62. PubMed ID: 9849454
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adult Pleomorphic Rhabdomyosarcoma: A Multicentre Retrospective Study.
    Noujaim J; Thway K; Jones RL; Miah A; Khabra K; Langer R; Kasper B; Judson I; Benson C; Kollàr A
    Anticancer Res; 2015 Nov; 35(11):6213-7. PubMed ID: 26504053
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of soft tissue sarcoma in childhood and adolescence. A report of the German Cooperative Soft Tissue Sarcoma Study.
    Koscielniak E; Jürgens H; Winkler K; Bürger D; Herbst M; Keim M; Bernhard G; Treuner J
    Cancer; 1992 Nov; 70(10):2557-67. PubMed ID: 1482503
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pooled analysis of phase II window studies in children with contemporary high-risk metastatic rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group.
    ; Lager JJ; Lyden ER; Anderson JR; Pappo AS; Meyer WH; Breitfeld PP
    J Clin Oncol; 2006 Jul; 24(21):3415-22. PubMed ID: 16849756
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early treatment failure in intermediate-risk rhabdomyosarcoma: results from IRS-IV and D9803--a report from the Children's Oncology Group.
    Minn AY; Lyden ER; Anderson JR; Million L; Arndt CA; Brown K; Hawkins DS; Donaldson SS
    J Clin Oncol; 2010 Sep; 28(27):4228-32. PubMed ID: 20713850
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relapse after localized rhabdomyosarcoma: Evaluation of the efficacy of second-line chemotherapy.
    Winter S; Fasola S; Brisse H; Mosseri V; Orbach D
    Pediatr Blood Cancer; 2015 Nov; 62(11):1935-41. PubMed ID: 26150380
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.